文献速递临床试验与 GCP基础与转化研究

基于生物标志物的早期临床试验适应性设计

Adaptive Biomarker-Based Design for Early Phase Clinical Trials.
PubMed 文献 · Stat Med · 2025-01-01

针对精准医学中预测性生物标志物的识别问题,提出一种单臂两阶段早期肿瘤试验的生物标志物指导设计,可在期中分析时决定提前终止、继续全人群或选定人群招募。模拟显示,尽管样本量有限,该设计较不考虑富集扩展的经典设计决策更优。

要点

  • 提出单臂两阶段早期肿瘤试验的生物标志物指导适应性设计。
  • 期中分析可决定提前终止、继续全人群或选定生物标志物亚组招募。
  • 模拟显示样本量有限时该设计决策优于不考虑富集扩展的经典设计。

核心结论

  • 所提出的单臂两阶段生物标志物指导设计在样本量有限时较不考虑富集扩展的经典设计决策更优。

研究设计与样本

  • 提出一种单臂两阶段早期肿瘤临床试验的生物标志物指导设计,在期中分析时决定提前终止、继续全人群或选定人群招募。

主要发现

  • 通过模拟显示,尽管样本量有限,所提设计较不考虑富集扩展的经典设计决策更优。

临床怎么用

  • 早期阶段目标并非精确界定目标人群,而是不遗漏可能仅限于生物标志物亚组的疗效信号。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying and quantifying predictive biomarkers is a critical issue of Precision Medicine approaches and patient-centric clinical development strategies. Early phase adaptive designs can improve trial efficiency by allowing for adaptations during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. At an early stage, the goal is not to precisely define the target population, but to not miss an efficacy signal that might be limited to a biomarker subgroup. In this work, we propose a one-arm two-stage early phase biomarker-guided design in the setting of an oncology trial where at the time of the interim analysis, several decisions can be made regarding stopping the entire trial early or continuing to recruit patients from the full or a selected patient population. Via simulations, we show that, although the sample size is limited, the proposed design leads to better decision-making compared to a classical design that does not consider an enrichment expansion.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Serra A, Saint-Hilary G, Guilleminot S, et al. Adaptive Biomarker-Based Design for Early Phase Clinical Trials. Stat Med. 2025. PMID: 41066076. doi:10.1002/sim.70275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。